-

05:31:57 PM

APRE Stock News

APRE - Aprea Therapeutics Inc

03/16/23 8:00 AM

Nasdaq : APRE

clinical trial

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that an

RHEA-AI

neutral

03/07/23 8:00 AM

Nasdaq : APRE

conferences

Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren

RHEA-AI

neutral

03/01/23 4:05 PM

Nasdaq : APRE

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it

RHEA-AI

neutral

02/27/23 4:05 PM

Nasdaq : APRE

offering

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the closing

RHEA-AI

neutral

02/22/23 8:41 PM

Nasdaq : APRE

offering

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the pricing

RHEA-AI

neutral

02/22/23 4:05 PM

Nasdaq : APRE

offering

Aprea Therapeutics Announces Proposed Public Offering of Common Stock

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced it has

RHEA-AI

neutral

02/15/23 8:00 AM

Nasdaq : APRE

Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received an award notification

RHEA-AI

positive

02/13/23 7:00 AM

Nasdaq : APRE

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced a one-for-twenty reverse

RHEA-AI

neutral

01/30/23 8:00 AM

Nasdaq : APRE

management

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Chief

RHEA-AI

very positive

01/19/23 8:00 AM

Nasdaq : APRE

conferences

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6 th

RHEA-AI

neutral

1 2 3 4 5 6 Next